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a b s t r a c t
In type 2 diabetes (T2D), treatment is optimised to minimise hyperglycaemia and the risk of
microvascular complications. While there are a number of effective treatments, intensive
treatment is associated with negative side effects such as increased hypoglycaemia and
weight gain.
With complementary modes of action, glucagon-like peptide-1 receptor agonists (GLP-
1RAs) and a basal insulin in combination offer an alternative to basal–bolus therapy in T2D.
This review describes the rationale behind this treatment combination and presents clinicalKeywords:
Type 2 diabetes
Insulin
GLP-1
Intensiﬁcation
data available for IDegLira, the ﬁrst basal insulin (insulin degludec) and GLP-1RA (liraglutide)
co-formulation available in one pen for a single injection daily.
© 2016 Primary Care Diabetes Europe. Published by Elsevier Ltd.
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. The need for treatment optimisation
he natural progression of type 2 diabetes (T2D), from
mpaired glucose tolerance through to overt T2D, is char-
cterised by increasing insulin resistance and decreased
ndogenous insulin production [1]. As deterioration in
eta-cell function continues beyond diagnosis, effective man-
gement of T2D typically requires therapy to bemonitored and
eriodically intensiﬁed to prevent worsening blood glucose
ontrol [2,3]. As such, current treatment guidelines recom-
end a stepwise approach to T2D therapy,with the addition of
econd- and third-line antidiabetic agents if glycaemic targets
re not met within 3 months. This involves regular monitor-
ng of the patient’s blood glucose with progression to daily
elf-measuring if the patient is prescribed insulin [1,4,5].
Chronic hyperglycaemia and poor glycaemic control
ncrease the risk of patients with T2D developing microvas-
ular complications such as retinopathy, neuropathy and
ephropathy [2,6,7]. In contrast, it is widely accepted that
mprovements in glycaemic control and intensive therapy
imed at reaching strict glycaemic targets can reduce the risk
f such microvascular complications developing and progres-
ing [2,6].
Unfortunately, despite the current guidelines, many
atients with T2D are still failing to meet glycaemic targets.
n the UK, more than two-thirds (73.8%) of patients with
2D are failing to meet the NICE-recommended intensive gly-
aemic control target of HbA1c < 6.5% [8]. This is the case
ven for those patients receiving insulin therapy, with more
han half of patients with T2D on basal insulin not achiev-
ng good glycaemic control [9–11]. While intensive treatment
as demonstrated signiﬁcant beneﬁts inT2D, treatment inten-
iﬁcation – particularly with insulin therapy – is associated
ith weight gain [2,12,13], an increase in the incidence of
ypoglycaemia [14] and a higher rate of severe hypoglycaemia
2,12,15]. There is, therefore, resistance among both patients
nd physicians to intensifying insulin therapy, with many
atients fearful of the increased risks of hypoglycaemia and
eight gain [16].
. Current treatment options
he aim of treatment in T2D is to maintain good glycaemic
ontrol (and thus reduce the risk of micro- and macrovascu-
ar complications) while at the same time reducing the risk of
dverse effects of therapy such as hypoglycaemia and weight
ain [4]. In recent treatment guidelines, there has also been
n increasing focus on individualising both therapy and goals
n T2D to best address patient needs [1]. For example, while
ecommending an overall HbA1c target of 6.5%, current NICE
uidelines for the management of T2D also emphasise the
eed for individualised, patient-centred care and involving
atients in their care decisions (e.g. HbA1c target setting) [4].
s part of this, there have also been calls to consider ear-ier initiation of both glucagon-like peptide-1 receptor agonists
GLP-1RAs) and basal insulin therapy in the treatment path-
ay [1], with thehope that thismight slowdisease progression
nd preserve some pancreatic function in some patients.0 ( 2 0 1 6 ) 202–209 203
As is evident in the current NICE clinical care pathway for
T2D (Fig. 1) [1], while there is awide range of treatment options
and a number of factors to take into account, treatment
usually follows a standardpattern of optimisation and intensi-
ﬁcation (Fig. 1) [1]. The ﬁrst line of treatment after diagnosis is
predominantly diet and lifestyle modiﬁcation, although some
may favour initiation of metformin at diagnosis depending
on the patient and their level of hyperglycaemia. Treatment
progression then usually proceeds with the subsequent inclu-
sion of additional oral antidiabetic drugs (OADs), such as
sulphonylureas or dipeptidyl peptidase-4 (DPP-4) inhibitors,
or GLP-1RAs as indicated when failure to control HbA1c with
metformin alone occurs [1,4]. After failure of glycaemic con-
trol on two or more OADs (including metformin), patients
will generally be initiated on basal insulin in order to reach
the agreed-upon glycaemic targets. Further optimisation may
include the addition of 1–3 bolus doses of prandial insulin
or additional basal insulin doses, although there has been
some suggestion that the use of twice-daily premixed insulin
may be preferable to basal–bolus treatment regimens in T2D
[17].
While the use of basal insulin is well established as effec-
tive in T2D, insulin therapy has traditionally been seen as a
treatment of last resort and there is evidence that physicians
delay both initiation and intensiﬁcation of insulin, even when
glycaemic control is poor [16,18]. Nevertheless, various studies
have investigated the effects of adding multiple bolus insulin
doses in various regimens in patients with insufﬁcient gly-
caemic control on basal insulin alone [19–22]. These studies
have demonstrated signiﬁcant glycaemic beneﬁts in T2D with
the addition of either a single bolus dose of insulin to basal
insulin and OADs [19] or the addition of multiple doses of
bolus insulin in either full basal–bolus or stepwise manner
[20–22]. Results from these studies show that, while there is
still discussion over howbest to intensify insulin therapy, such
treatment is effective in T2D.
Unfortunately, the HbA1c reduction achieved with treat-
ment intensiﬁcation is often accompanied by weight gain,
an increased risk of hypoglycaemia and the requirement
to administer and adjust additional daily insulin injections
[2,12–14,23]. Fear of these side effects can lead to both patients
and physicians delaying initiation of insulin and, once initi-
ated, increasing insulin dose or adding additional injections
[16].
Because of these issues, several published studies have
investigated the feasibility of combining GLP-1RAs with basal
insulin as an alternative to basal–bolus insulin therapy in
T2D [24–26]. There is also some evidence that the use of
these drug classes together is becoming more common in
the clinic, particularly with the addition of liraglutide to basal
insulin [27]. Nevertheless, this approach still requires multiple
daily injections and is subject to the gastrointestinal-related
side effects associated with the initiation and uptitration
of GLP-1RAs. However, a ﬁxed-ratio combination of these
agents, with slow titration, has the potential to address
both fasting and postprandial control without incurring the
tolerability issues associated with prandial insulins and
the gastrointestinal-related side effects of GLP-1RAs [24–26];
hence there is a rationale for developing such a combination
product.
204 pr imary care d iabetes 1 0 ( 2 0 1 6 ) 202–209
Fig. 1 – Care pathway for treatment of type 2 diabetes [1]. A1c, glycated haemoglobin (HbA1c); DPP-4i, dipeptidyl peptidase-4
inhibitor; Fx, bone fracture; GI, gastrointestinal; GLP-1RA, glucagon-like peptide-1 receptor agonist; HF, heart failure; SU,
sulphonylurea; TZD, thiazolidinedione. Reproduced with kind permission from Springer Science+Business Media:
Diabetologia 55 (2012) 1577–1596.
3. Combining basal insulin and GLP-1RA
effects: IDegLira
The GLP-1RA component of IDegLira, liraglutide, is a once-
daily human GLP-1 receptor agonist (GLP-1RA) that shares a
97% amino acid sequence identity with human GLP-1 [28,29].
The efﬁcacy and safety of liraglutide has been demonstrated
via the LEAD phase 3 clinical trial programme, which included
a total of 4456 subjects, 2739 of whom were treated with
liraglutide [30–36]. A meta-analysis of the phase 3 data has
shown a mean reduction in HbA1c of 1.5% with liraglu-
tide 1.8mg and 1.3% with liraglutide 1.2mg when added
to unchanged background treatment (vs. 0.3% with placebo,
p<0.0001) [37]. As with other GLP-1RAs, liraglutide also shows
beneﬁts regarding body weight in T2D with signiﬁcantly
greater loss with liraglutide than placebo or active compara-
tors [38].
The insulin component of IDegLira, insulin degludec, is a
long-acting basal insulin analogue with a half-life twice as
long as that of insulin glargine and low day-to-day variabil-
ity in glucose-lowering effect [39,40]. The efﬁcacy of insulindegludec in T2D as part of both basal–bolus therapy and basal-
only therapy has been assessed as part of the BEGIN phase
3 clinical trial programme [41–44]. In insulin-naïve patients
with T2D, insulin degludec has demonstrated comparable gly-
caemic control to insulin glargine when titrated to a common
blood glucose target but with a signiﬁcantly lower rate of noc-
turnal hypoglycaemia (43% lower than with glargine, p=0.002)
after 2 years of treatment [44]. As part of a basal–bolus regimen
inT2D, insulindegludecwas shown toprovide comparable gly-
caemic control to insulin glargine butwith an 18% lower rate of
overall hypoglycaemia (p=0.0359) and a 25% lower rate of noc-
turnal hypoglycaemia (p=0.0399) over 52 weeks of treatment
[41].
The concept of treating T2D with basal insulin and a GLP-
1RA in combination is particularly appealing as the two drug
classes address different aspects of the pathophysiological
deﬁcits in T2D. Separately, each can safely and effectively
help many patients achieve recommended glucose targets
when they are no longer able to do so with lifestyle mod-
iﬁcation and OADs alone [23,45]. Together, they may have
complementary actions, with basal insulin providing a reduc-
tion in fasting blood glucose while the GLP-1RA ameliorates
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ostprandial excursions due to the glucose-dependent mech-
nism of action.
Given this potential for complementary glucose-lowering
ffects, the addition of liraglutide to basal insulin (insulin
egludec) therapy has already been explored in T2D [24]. In
study in patients inadequately controlled on basal insulin
nd metformin, the addition of liraglutide (1.2mg increased
o 1.8mg if fasting plasma glucose [FPG] ≥5.0mmol/L at week
) was compared with the addition of a single bolus dose
f insulin aspart [24]. The results showed a greater reduc-
ion in HbA1c with liraglutide than aspart (−0.74% vs. −0.39%,
< 0.001), with lower rates of hypoglycaemia and a weight loss
f 2.8 kg versus weight gain with insulin aspart [24].
While several such combination products are currently in
evelopment or clinical trials, IDegLira is the ﬁrst combination
f a basal insulin analogue (degludec) and a GLP-1RA (liraglu-
ide) in single daily injection to be approved for use in Europe.
DegLira is administered via a pre-ﬁlled pen with a ﬁxed ratio
f insulin degludec (100U/mL) and liraglutide (3.6mg/mL).
DegLira uses a simpliﬁed titration algorithm based on dose
teps, with each dose step consisting of one unit of insulin
egludec and 0.036mg liraglutide. The initial dose of IDegLira
s 10 dose steps (10units of insulin degludec and 0.36mg
iraglutide) in individuals uncontrolled on OADs and 16 dose
teps (16units of insulin degludec and 0.6mg liraglutide) in
hosepreviously receivingbasal insulin or aGLP-1RA.Thedose
s adjusted based on self-measured blood glucose targets and
ith a maximum dose, per injection once daily, of 50units of
nsulin degludec and 1.8mg liraglutide [46].
. Comparison with individual components
o date, data have been published from two phase 3a clini-
al trials of IDegLira, one in insulin-naïve patients and one in
atients previously treated with basal insulin.
The ﬁrst of these (DUAL I) was a randomised, open-label
tudyof IDegLira versus insulin degludec or liraglutide alone in
Table 1 – Response to IDegLira in phase 3a and phase 3b clinica
Citation Trial
name
Trial
duration
Prior
treatment
Comparator
Gough
et al.
[47]
DUAL I
main trial
26 weeks Metformin±
pioglitazone
IDegLira vs.
IDeg;
IDegLira vs.
liraglutide
Buse et al.
[49]
DUAL II 26 weeks Basal insulin+
metformin±SU
IDeg (max.
dose 50U)
CI, conﬁdence interval; ETD, estimated treatment difference; ERR,
degludec/liraglutide; PYE, patient-year of exposure; SU, sulphonylurea.
∗ Severe, or plasma glucose <56mg/dL.0 ( 2 0 1 6 ) 202–209 205
insulin-naïve patients previously treatedwithmetforminwith
or without pioglitazone [47]. The main trial of 26 weeks was
extended to a year to assess the durability of the treatment
effect [48]. The starting dose for both IDegLira and insulin
degludec was 10 dose steps/units and dose adjustments were
made twice weekly (±2 dose steps/units to an FPG target of
4.0–5.0mmol/L). The starting dose for liraglutide was 0.6mg
with titration up to 1.8mg by 0.6mg per week, as per the label.
In the second study (DUAL II), a randomised, double-blind
trial of IDegLira versus insulin degludec in patients previously
receiving 20–40units of basal insulin, the starting dose for
both IDegLira and insulin degludec was 16 dose steps/units,
again with dose adjustments made twice weekly (±2 dose
steps/units to an FPG target of 4.0–5.0mmol/L). However, in
this study, the maximum dose of insulin degludec in both
the IDegLira and insulin degludec arms was capped at 50
dose units [49]. This was in order to speciﬁcally demonstrate
the additional contributions of the liraglutide component of
IDegLira.
In the results published to date, IDegLira has demon-
strated several signiﬁcant beneﬁts over each of the individual
components in both insulin-naïve patients [47] and in those
previously treated with basal insulin [49] (summarised in
Table 1). In insulin-naïve patients, IDegLira produced a sig-
niﬁcantly greater reduction in HbA1c (−1.9%) than either
degludec (−1.4%) or liraglutide (−1.3%) after 26 weeks’ treat-
ment (p<0.0001 for both) (Fig. 2) [47,49].
Improvement in HbA1c was accompanied by a mean body
weight reduction of −0.5 kg with IDegLira, compared with a
weight increase of 1.6 kg with degludec (p<0.0001 vs. IDegLira)
and a weight loss of 3.0 kg with liraglutide (p<0.0001 vs.
IDegLira). In addition, a signiﬁcantly greater proportion of the
IDegLira group reached glycaemic targets of HbA1c <7.0% (81%
with IDegLira vs. 65% with insulin degludec and 60% with
liraglutude, p<0.0001) and ≤6.5% (70% with IDegLira vs. 48%
with insulin degludec and 41% with liraglutide, p<0.0001).
The additional glucose-lowering effect provided by liraglu-
tide in the combination also reduces the dose of insulin
l trials [47,49].
HbA1c IDegLira
vs. comparator,
ETD (%)
body weight
IDegLira vs.
comparator,
ETD (kg)
Hypoglycaemia*
events/PYE,
IDegLira vs.
comparator, ERR
−1.9 vs.
−1.4%,−0.47%
[−0.58; −0.36]95% CI,
p<0.0001;
−0.5 vs. 1.6 kg,
−2.22kg
[−2.64; −1.80]95% CI,
p<0.0001;
1.8 vs. 2.6, 0.68
[0.53; 0.87]95% CI,
p=0.0023;
−1.9 vs. −1.3, −0.64%
[−0.75; −0.53]95% CI,
p<0.0001
−0.5 vs. −3.0 kg,
2.44 kg
[2.02; 2.86]95% CI,
p<0.0001
1.8 vs. 0.2, 7.61
[5.17; 11.21]95% CI,
p<0.0001
−1.9 vs. −0.9%,
−1.1%
[−1.3; −0.8]95% CI,
p<0.0001
−2.7 vs. 0.0 kg,
−2.5 kg
[−3.2; −1.8]95% CI,
p<0.0001
1.5 vs. 2.6, 0.66
[0.39; 1.13]95% CI,
p=0.13
estimated rate ratio; IDeg, insulin degludec; IDegLira, insulin
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Fig. 2 – Change in HbA1c from baseline with IDegLira and comparators in (a) insulin-naïve patients [47] and (b) patients
udecpreviously treated with basal insulin [49]. IDeg, insulin degl
required to reach the same glycaemic target. In DUAL I, the
end-of-trial insulin dose was 28% lower with IDegLira than
insulin degludec (38 vs. 53units, p<0.0001), despite the signif-
icantly greater reduction in H
bA1c with IDegLira [47]. This reduced dose of the insulin
component likely contributes to the signiﬁcantly (32%,
p=0.0023) lower rate of hypoglycaemia seen with IDegLira
than with degludec in this trial, despite the lower end-of-
trial HbA1c (6.4 vs. 6.9% [46 vs. 52mmol/mol]). As would be
expected, few subjects reported hypoglycaemia with liraglu-
tide. Results of the DUAL I extension study showed that the
efﬁcacy and safety of IDegLira demonstrated in the main trial
were maintained for a year [48].
Interestingly, in DUAL I, the proportion of patients expe-
riencing nausea with IDegLira was signiﬁcantly lower with
IDegLira than with liraglutide over the full course of the main
trial (Fig. 3) [47]. This is likely due to the slower titration of
Fig. 3 – Proportion of patients experiencing nausea with
IDegLira versus liraglutide in the DUAL I study [47]. IDeg,
insulin degludec; IDegLira, insulin degludec/liraglutide.
Reprinted from Lancet Diabetes Endocrinol. 2 (2014)
885–893, with permission from Elsevier Ltd.; IDegLira, insulin degludec/liraglutide
liraglutide as part of the combination, where the increase
in dose was based on titration of the degludec component
compared with liraglutide, in which the standard liraglutide
titration was followed. IDegLira is now approved in Europe
for use in patients uncontrolled on GLP-1RA therapy and oral
glucose-lowering products [46]; results from a phase 3b trial
in which patients with T2D inadequately controlled on GLP-
1RA therapy (maximum dose tolerated or locally approved)
were randomised to either switch to IDegLira, with initiation
at 16 dose steps, or to continue on unchanged GLP-1RA ther-
apy, demonstrated that IDegLira was superior with respect to
mean HbA1c reduction in this population. The mean IDegLira
dose after 26 weeks of treatment was 43 dose steps, which cor-
responds to 43units of insulin degludec and1.55mg liraglutide
[50].
In patients previously treated with basal insulin, IDegLira
demonstrated signiﬁcantly greater reduction in HbA1c com-
pared with insulin degludec after 26 weeks of treatment
(−1.9% vs. −0.9%, p<0.0001) (Fig. 2) [49]. In these patients,
IDegLira produced a mean weight loss of 2.7 kg compared with
no weight change with insulin degludec.
Rate of conﬁrmed hypoglycaemia (including severe events
and deﬁned as plasma glucose <3.1mmol/L regardless of
symptoms, or if required assistance) was comparable between
the two groups (1.5 vs. 2.6 events/patient-year; p=not sig-
niﬁcant) with similar incidences (IDegLira 24% vs. insulin
degludec 25%) and a lower end-of-trial HbA1c with IDegLira
(6.9% vs. 8.0%) [49].
In both of these phase 3a studies, IDegLira demonstrated
superior HbA1c control to either of the components, basal
insulin degludec or liraglutide, alone. IDegLira also demon-
strated additional beneﬁts of a single injection rather than
multiple daily insulin doses and a decreased incidence of
nausea (a common side effect of GLP-1RAs), and the weight
gain that is a characteristic of treatment with basal insulin.
These data suggest potential beneﬁts of IDegLira in patients
with insufﬁcient glycaemic control but for whom weight loss
and/or avoidance of an increased risk of hypoglycaemia is
desirable.
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. Clinical considerations
DegLira is given once daily by subcutaneous administration.
t can be given at any time of the day, preferably at the same
ime each day.
Dosing of IDegLira is done in ‘dose steps’ rather than units
s each dose step contains one unit of insulin degludec and
.036mg of liraglutide. The titration algorithmwill be based on
he average of three morning blood glucose readings [46]. For
atients who are adding IDegLira to existing OADs, the recom-
ended starting dose is 10 dose steps. IDegLira can be added
o existing OADs, but a reduction in the dose of sulphonylurea
hould be considered when added to sulphonylurea therapy.
ny therapy with basal insulin should be discontinued prior
o initiation of IDegLira, and when transferring from basal
nsulin therapy, the recommended starting dose of IDegLira
s 16 dose steps [46]. Similarly, for patients currently uncon-
rolled with a GLP-1RA, existing GLP-1RA therapy should be
iscontinued prior to initiation of IDegLira at a starting dose
f 16 dose steps. This corresponds to a starting dose of 0.6mg,
s recommended for patients beginning liraglutide treatment
51].
. Conclusions
ue to the progressive nature of T2D, the majority of patients
ill require increasing intensiﬁcation of treatment in order
o maintain good glycaemic control and a large proportion
f patients will eventually require insulin therapy. Unfortu-
ately, while the initiation of insulin and intensiﬁcation of
nsulin therapy with additional bolus doses has proven efﬁ-
acy in T2D, it is associated with signiﬁcant side effects such
s weight gain and hypoglycaemia.
The combination of GLP-1RAs with basal insulin has been
nvestigated in T2D populations in several clinical trials with
ositive results. IDegLira is the ﬁrst basal insulin and GLP-1RA
n one pen for a once-daily injection and offers a new treat-
ent option for patients who require treatment optimisation.
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